// App-Quantinova.ai

1982 : Safety and Efficacy of a Six Month Full Dose Lenalidomide Consolidation Treatment After First-Line High-Dose Therapy in Patients with Multiple Myeloma

Researchers

Presenter

  • Julia Baier

Principal Investigators

  • Aristoteles Giagounidis

  • Thomas Schroeder

  • Lars Galonska

  • Norbert Gattermann

  • Rainer Haas

  • Guido Kobbe

  • Mathias J. Rummel

  • Nicolaus Kroger

  • Tobias Strapatsas

  • Ariane Dienst

  • Esther Zipperer

  • Kathrin Nachtkamp

  • Alexander Burchardt

Medical Centers

  • Hmeatology, Oncology and clinical Immunology, Heinrich Heine University, Duesseldorf, Germany

  • Rheumatology, Justus-Liebig-University Giessen, Giessen, Germany

  • Oncology and Clinical Immunology, Heinrich-Heine-Universitat Universitatsklinik, Dusseldorf, Germany

  • Department of Hematology, Oncology and Clinical Immunology, Universitaetsklinikum Duesseldorf, Duesseldorf, Germany,

  • Heinrich-Heine-Universitat, Dusseldorf, Germany

  • Dept. of Hematology & Center of Oncology - Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  • Molekularbiologisches Labor, Klinik fur Hamatologie, Onkologie und klinische Immunologie, Dusseldorf, Germany

  • Hmeatology, Oncology and clinical Immunology, Heinrich Heine University, Duesseldorf, Germany

  • Medizinische Klinik II, St. Johannes Hospital, Duisburg, Germany

  • Justus-Liebig University of Giessen, Giessen, Germany

  • Hematology, Oncology and Clinical Immunology, Heinrich Heine University Duesseldorf, University Hospital, Duesseldorf, Germany

  • Department of Obstetrics and Gynaecology, University Hospital Duesseldorf, Duesseldorf, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Deep vein thrombosis

  • Multiple Myeloma

  • Thrombocytopenia

  • Neutropenia

  • Venous thrombosis

  • Anemia

Biomarkers

  • Cluster of differentiation 79A

  • Immunoglobulin G

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Lenalidomide

  • Melphalan

  • Aspirin

  • Albyl-E

Outcome

  • N/A

Study Design

  • open label

  • randomized

  • pharmacodynamics

Phase

  • NA

Study Id's

  • NCT00891384

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved